(+34) 985 980 098 / 985 98 06 05 sales@nanovexbiotech.com



Exosomes are extracellular vesicles of natural origin that are produced by all cell types in the range of 40 to 160 nm. They have a key role in cell-to-cell communication and have been proved to be powerful tools in diagnosis and therapeutics.

Their basic structure is very similar to liposomes, consisting of double lipid which is a slice of cell membrane and an aqueous based core which will be a part of cell plasma. For this reason, exosomes are rich in biological molecules, containing transmembrane proteins and receptors in their surface, as well as comprising nucleic acids, amino acids, metabolites, and other molecules within.

Exosomes then, act as delivery agents, for different biological purposes:

  • Genetic expression regulation
  • Survival and proliferation signalling
  • Angiogenesis and wound healing stimulation
  • Waste management
  • Immunity triggering and balance
  • Receptor ligand specific signalling
  • Apoptosis control
  • Cellular differentiation
  • Indication of cellular migration and metastasis
  • Metabolic programming

As mentioned above, exosomes are produced by all types of cells, and are formed by the endogenic pathway. The cell membrane folds inward, in a process called invagination, forming a lipid vesicle: the endosome. Then, inside the cell, macromolecules as proteins and genetic material are incorporated into the endosome, again by invagination, creating multiple exosomes. Finally, the endosome membrane fuses with the cell membrane to release these vesicles to be received by other cells.

Natural exosomes are very difficult to obtain and require expensive and strict purification and analytical procedures. For this reason, multiple technologies have been developed to synthesize extracellular vesicles very similar to exosomes.


Synthetic exosomes are outstanding drug carriers since they resemble cellular communication mechanisms. However, unlike natural exosomes, size and composition can be easily controlled and scalable for its use in preclinical or clinical settings. Since the assembly process can be monitored, it results in the formation of “clean”, well-characterized drug delivery systems. To date, exosomes have been used in many studies for tissue regeneration, delivery of drugs and genes, and diagnosis of diseases.


Although exosomes are greatly heterogeneous, they can be classified according to the following criteria:


There are three main groups of exosomes according their size: Exo A: 40-75 nm, Exo B: 75-100 nm and Exo C: 100-160 nm.


There are three transmembrane proteins used to identify exosomes: CD63, CD9 and CD81

Cell function

Exosomes as was stated earlier, serve many purposes, and can be classified as pro-survival, pro-apoptotic and immunomodulating.


All cell types produce exosomes, so their source is also a classification tool: brain-derived exosomes, liver-derived exosomes and pancreas-derived exosomes are three examples.


Natural exosomes produced endogenously by cells present some limitations such as homogeneity, expensive and difficult isolation as well as poor targeting specificity. For application in the clinical field, loading of exosomes with pharmaceuticals and targeting are required. For those reasons, several alternatives have been developed. Mainly, those being hybrid and synthetic exosomes.


Alteration of natural exosomes has been labelled under the umbrella term of engineered or designer exosomes. The aim of this process is to display targeting molecules or loading therapeutical compounds within. This type of exosomes can be obtained by two different approaches, through parental cell-based engineering or direct post-isolation engineering, from more to less complex.

In the first case, the cells are genetically modified to produce exosomes with the components of interest in vivo. With this approach, labelling or targeting proteins can be placed in the surface or other components delivered inside. An example could be the production of a protein with an exosome signalling peptide (CD63, CD9, CD81, GPI and Lamp2b), that will lead to the embedding in the exosome membrane. If the molecule is desired to be transported within, other tags can be used to direct the MSMs or Molecule Sorting Module system. This MSMs is the responsible for sorting the proteins and RNA that will be directed to the exosome. For example, ubiquitination tags have been proved to help in this process.

The second approach, direct post-isolation engineering, involves the modification of the exosomes after the isolation has been done. The addition of molecules in the exosomes can be achieved by manipulation methods such as sonication extrusion, incubation, freeze-thaw and bioconjugation. Another strategy for post-isolation modification is the fusion with synthetic liposomes containing the desired components, producing what are called hybrid exosomes.


In the bottom-up strategy we have fully synthetic or artificial exosomes using plain liposomes as a blank canvas and adding the characteristic exosome markers, lipids and contents (proteins and RNA). Also referred to as exosome-mimetics, the synthetic exosomes are less variable and allow the incorporation of targeting ligands and contents in an easier and controlled manner. They are more suitable for pharmaceutical uses since they are highly reproducible and easier to scale up the manufacturing.
















Validation and quality control: Detection and characterization of exosomes is necessary to stablish a relationship to disease and therapy. However, the low quantities obtained during isolation together with its cost, does not make it the ideal control for the development of reliable detection techniques. Synthetic exosomes are a very interesting tool to use as a standard in different applications such as the validation of exosome isolation tools or detection systems, among others.

Cancer treatment: Like other nanocarriers, synthetic exosomes can be used to treat different types of cancer successfully, by encapsulating the desired anti-tumoral drug or RNA and enzymes. Several studies have used engineered exosomes from dendritic or macrophage cells to release chemotherapeutic compounds as doxorubicin, paclitaxel miRNA or siRNA to induce antitumoral activity. Rodent mammary carcinoma, mice lung cancer, glioma and pancreatic cancer are just some targeted diseases in preclinical testing using exosome delivery technology. Examples of peptides and targeting ligands for exosome decoration are integrin specific RGD for mice mammary tumor or GE11 synthetic peptide for EGFR+ breast cancer.

Immunomodulating response: Downregulating the immune response is necessary for the treatment of autoimmune diseases. In this aspect, the APO2L/TRAIL ligand is a key intermediate in immune cascades and is secreted in exosomes in natural conditions. Its alteration has been associated with rheumatoid arthritis. The administration of synthetic exosomes decorated with APO2L/TRAIL has been shown to be effective in reducing the hyperplasia and overall inflammation in this disease.

In the opposite case, cancer, it is necessary to bring the developed auto-tolerance down. APO2L/TRAIL also shows anticarcinogenic activity by inducing apoptosis in tumoral cells through the activation of the caspase-3. Additionally, exosomes derived from dendritic cells, exert a great power over the activation of T cell responses. Synthetic or engineered exosomes can mimic the dendritic cell exosomes by incorporating complexes of MHC Class I peptides and other T-cell receptors.

Molecular therapy: Exosomes are natural genetic material carriers, including mRNA, miRNA and siRNA. This material cannot be used in its naked form since it is very sensitive to degradation by ribonucleases, and it cannot enter the cells freely. Encapsulation in synthetic exosomes is an advantageous approach: it preserves the RNA and allows a path for cell uptake.

Ocular drug delivery: Drug delivery in the retina is normally performed through intravitreal injection but it is only suitable for compounds fitting a list of criteria like long half-lives. Decoration of engineered exosomes derived from retinal cells with hyaluronan binding peptides is a very effective alternative to intravitreal injection. Hyaluronan can be found in high concentrations in the vitreous of the eye, and thus, this strategy enhances the penetration and uptake from retina cells.

Brain drug delivery: The delivery of therapeutical compounds such as RNA drugs into the brain presents the challenges of RNA preservation and the crossing of the blood brain barrier. Exosomes loaded with the specific siRNA sequences and marked with the neuron specific RVG peptide show specific accumulation in neurons, microglia and oligodendrocytes in the brain, effectively reducing genetic expression. This is a potential approach for brain diseases like Alzheimer, while reducing side effects due to unspecific tissue targeting.

Tissue regeneration: Synthetic exosomes formulated to have a similar composition to those produced by mesenchymal stem cells, fibrocytes and keratinocytes show great repairing and healing properties, stimulating neovascularization, cell proliferation and inhibiting inflammation. They can also be loaded with regenerative drugs, RNA or growth factors to enhance their effect.


Proteins and enzymes

Genetic material

Lipophilic compounds

Pharmaceutical drugs


The heterogeneity of exosomes depends on the cell source and its function. Exosome composition is complex and is not viable to artificially incorporate every protein and RNA present in a cell-secreted exosome. For this reason, it is key to first understand what are the contents that lead to the functionality of the exosome. The most important ones are membrane ligands and RNAs.

Tetraspanins from exosomes

Tetraspanins are transmembrane proteins with four hydrophobic domains inserted in the lipidic membrane. They are key players in the signal transduction field, where they play a part in cell proliferation, adhesion, membrane fusion, immune system activation, protein trafficking and cell migration. CD9, CD81 and CD63 are the main membrane proteins present in natural exosomes, being considered exosome markers. They are indispensable for exosome mimics.

  • CD81 tetraspanin: it complexes with integrins, with the immunoglobulin superfamily member 8 and CD36. It has been related to the stimulation of cell proliferation and signal transduction, interacting with membrane proteins of the B cell and T cells, and as such, having immunomodulatory effects.
  • CD9 tetraspanin: it interacts with other tetraspanins (CD63) as well as with integrins (α1β1), immunoglobulin SF members (intercellular adhesion molecule 1 or CD54), growth factors (Pro-TGF-α) and immune system molecules (CD4). It has a role in platelet activation and aggregation, and immune response by interaction with neutrophils. Studies show that is also involved in cancer metastasis since it regulates cell adhesion and migration.
  • CD63 tetraspanin: It associates with integrins (CD18), TIMP-1 and other viral proteins. As other tetraspanins, it participates in migration, proliferation, and cell signalling.

Other ligands

  • Glycosylphosphatidylinositol (GPI)
  • Platelet-derived growth factor receptors (PDGFRs)
  • Lactadherin (C1C2 domain)
  • APO2L/TRAIL: For immune regulation, tumoral cells targeting
  • MHC peptide complexes: T-cell targeting
  • Antibodies: For example, DEC205 monoclonal antibody for specific targeting of dendritic cells to induce immune responses.
  • Integrin α6β4: Binds to laminins, for targeted delivery in cancer cells (lung)
  • Cx43 proteins: Conexin protein that allows cellular communication, involved in the coordination of muscle contraction and inflammation


Exosome physico-chemical properties must be tailored to every delivery project to yield the expected therapeutical effects.

Regarding exosome composition, there is a wide range of phospholipids with different features that allow the control of its targeting abilities:

  • Fluorescence phospholipids for tracking and imaging applications
  • Cationic phospholipids for gene delivery
  • Anionic phospholipids like phosphatidylserine for immune system targeting
  • PEGylated phospholipids for stealth delivery
  • Functionalized head groups for the covalence union of the lipid with targeting compounds such as peptides or antibodies
  • pH ionizable phospholipids for mRNA delivery
  • Addition of coating compounds for targeting like chitosan, PEI, pectin, or hyaluronic acid

The physical properties such as size and lamellarity are closely related to its pharmacokinetics and drug loading capacity. They depend on the composition but mainly on the production methods, and thus, can be adjusted for each target.

Size and lamellarity are directly proportional to the amount of drug it can encapsulate since they increase the volume of the compartments accommodating both hydrophilic (core) and hydrophobic (membrane) compounds.


Do you have a drug delivery project compatible with synthetic exosomes? Get in contact with us and tell us a little bit about your project. We will assess you and prepare a synthetic exosome design that ensures your success.